Gene may open door for improved keloid, scar treatment

Jan. 27, 2015

Researchers at Henry Ford Hospital in Detroit have identified a gene that may offer a better understanding of how keloid scars develop and potentially open the door to improved treatment. The study is the first to demonstrate that an altered AHNAK gene may have a significant biological role in keloid development. Study results were presented last week at the 2015 Triological Combined Sections Meeting in San Diego.

Keloid scars form raised firm skin areas and most often occur on the chest, shoulders, earlobes (following ear piercing), upper arms and cheeks. Unlike regular scars, keloids do not subside over time and often extend outside the wound site. The lowest rates of keloid formation have been documented in albinos and the highest seen in dark skinned individuals, especially in the African-American population.

Treatment for keloids includes cortisone injections, pressure dressings, silicone gels, surgery, cryosurgery (freezing), laser treatment, or radiation therapy. A combination of treatments may be used, depending on the individual. In some cases, keloids return after treatment, up to 50 to 100 percent of the time. AHNAK is a 700 kDa protein located on the cell membrane in epithelial cells and in the nucleus and cytoplasm of other cell types such as fibroblasts. AHNAK has been suspected to contribute to cell-cell adhesion or exocytosis.

For their study, the researchers investigated AHNAK as a potential biomarker in keloids through the integration of methylation and gene expression. To do so, the Henry Ford team examined samples of fresh keloid tissue and fresh normal tissue for AHNAK expression. Three of the five keloid samples showed a large reduction in expression as compared to the normal tissue. In this small sample, gene expression was consistent with methylation, a process that allows the researchers to look for genetic abnormalities within tumor samples.

Read the full press release on the Henry Ford Hospital website